Combined hepatocellular-cholangiocarcinoma: a contemporary pathologic and molecular perspective [0.03%]
结合肝细胞癌和胆管癌的病理及分子特征的当代研究视角
Taek Chung
Taek Chung
Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma characterized by the unequivocal coexistence of hepatocytic and cholangiocytic differentiation within a single tumor. Despite its low incidence, cHCC-CC...
Alcohol-related hepatocellular carcinoma: Surveillance and primary prevention [0.03%]
酒精相关肝细胞癌的筛查和一级预防
Gianni Testino
Gianni Testino
The role of radiotherapy in the management of combined hepatocellular-cholangiocarcinoma: current evidence and future perspectives [0.03%]
放疗在肝细胞癌-胆管癌混合型肿瘤治疗中的作用：现有证据及未来展望
Seo Hee Choi,Woong Sub Koom,Ik Jae Lee
Seo Hee Choi
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare and highly aggressive hybrid malignancy characterized by a poor prognosis and high recurrence rates due to its dual histological nature. In the absence of established standard-...
Imaging differentiation of hepatocellular carcinoma, combined hepatocellular-cholangiocarcinoma, and intrahepatic cholangiocarcinoma: pitfalls and advances [0.03%]
肝细胞癌、混合性肝细胞-胆管癌和肝内胆管癌的影像鉴别：陷阱与进展
Jaeseung Shin,Taek Chung,Sang Yun Ha et al.
Jaeseung Shin et al.
Accurate non-invasive differentiation of primary liver cancers, such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and combined hepatocellular-cholangiocarcinoma (cHCC-CCA), is crucial for optimal management but...
Contemporary overview of liver transplantation for intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma [0.03%]
现代肝移植治疗肝内胆管癌和混合型肝细胞-胆管癌综述
Hae Won Lee
Hae Won Lee
Historically, intrahepatic cholangiocarcinoma (iCCA) and combined hepatocellular-cholangiocarcinoma (cHCC-CCA) were regarded as absolute contraindications for liver transplantation (LT) due to dismal outcomes characterized by high recurrenc...
Systemic therapy for combined hepatocellular-cholangiocarcinoma: a comprehensive review of chemotherapy, immunotherapy, and targeted therapy [0.03%]
结合肝细胞癌和胆管癌的系统治疗：化疗、免疫治疗和靶向治疗综述
Jung Yong Hong,Dong Hyun Sinn,Sang Yun Ha
Jung Yong Hong
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver malignancy exhibiting both hepatocytic and cholangiocytic differentiation. Since the 2019 World Health Organization (WHO) reclassification, growing molecular and ...
Systemic treatment strategies for combined hepatocellular-cholangiocarcinoma: current evidence and future direction [0.03%]
结合肝细胞癌和胆管癌的系统治疗策略：现有证据及未来方向
Jeesun Yoon
Jeesun Yoon
Combined hepatocellular-cholangiocarcinoma is a rare primary liver malignancy characterized by biphenotypic differentiation and marked biologic heterogeneity. Owing to its low incidence, diagnostic complexity, and lineage plasticity, standa...
Liver resection versus radiofrequency ablation or transarterial chemoembolization for early multinodular BCLC-A hepatocellular carcinoma: a systematic review and meta-analysis [0.03%]
肝切除与射频消融或经导管动脉化疗栓塞治疗巴塞罗那分期BCLC-A期多结节小肝癌：系统评价和 Meta 分析
Maria F F Viana,Arthur A Braga,Lucas B Carvalho et al.
Maria F F Viana et al.
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, with high mortality rates worldwide. The optimal treatment strategy for patients with multinodular early-stage HCC (BCLC-A) is still controversial, particularly regardi...
Surgical Management of Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma: A Narrative Review of Principles, Technical Nuances, and Emerging Strategies [0.03%]
肝内胆管癌和混合型肝细胞-胆管癌的外科治疗：原则、技术要点及新兴策略的叙述性回顾
Woohyung Lee,Kwang Pyo Hong,Jae Hoon Lee et al.
Woohyung Lee et al.
Intrahepatic cholangiocarcinoma (CCA) is the second most common primary liver cancer after hepatocellular carcinoma (HCC). However, combined HCC-CCA is a rare malignancy exhibiting hepatocytic and cholangiocytic differentiation. For both tu...
Immune-related adverse events in hepatocellular carcinoma: organ-specific patterns and management approaches [0.03%]
免疫相关不良事件在肝细胞癌中的器官特异性模式和管理方法
Sul Ki Choi,Seonjeong Woo,Hong Jae Chon
Sul Ki Choi
Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide. The recent introduction of immune checkpoint inhibitors (ICIs) has transformed the therapeutic landscape of advanced HCC. Combination regimens such as at...